NEW AWARD - TRANSGENIC T CELL IMMUNOTHERAPY TARGETING PROSTATE-RESTRICTED EPITHELIAL ANTIGENS IN PROSTATE CANCER, EFFECTIVE 3/1/2020, SIGNED 2/21/2020, DISTRIBUTED 2/24/2020, FAADC 2/24/2020
$350,141FY2020Defense Health AgencyDOD
Fred Hutchinson Cancer Research Center, Seattle WA